Abstract:The chemokine CXCL12 and its G protein-coupled receptor (GPCR) CXCR4 are high-priority clinical targets because of their involvement in metastatic cancers (also implicated in autoimmune disease and cardiovascular disease). Because chemokines interact with two distinct sites to bind and activate their receptors, both the GPCRs and chemokines are potential targets for small molecule inhibition. A number of chemokines have been validated as targets for drug development, but virtually all drug discovery efforts focus on the GPCRs. However, all CXCR4 receptor antagonists with the exception of MSX-122 have failed in clinical trials due to unmanageable toxicities, emphasizing the need for alternative strategies to interfere with CXCL12/CXCR4-guided metastatic homing. Although targeting the relatively featureless surface of CXCL12 was presumed to be challenging, focusing efforts at the sulfotyrosine (sY) binding pockets proved successful for procuring initial hits. Using a hybrid structure-based in silico/NMR screening strategy, we recently identified a ligand that occludes the receptor recognition site. From this initial hit, we designed a small fragment library containing only nine tetrazole derivatives using a fragment-based and bioisostere approach to target the sY binding sites of CXCL12. Compound binding modes and affinities were studied by 2D NMR spectroscopy, X-ray crystallography, molecular docking and cell-based functional assays. Our results demonstrate that the sY binding sites are conducive to the development of high affinity inhibitors with better ligand efficiency (LE) than typical protein-protein interaction inhibitors (LE ≤ 0.24). Our novel tetrazole-based fragment 18 was identified to bind the sY21 site with a K(d) of 24 μM (LE = 0.30). Optimization of 18 yielded compound 25 which specifically inhibits CXCL12-induced migration with an improvement in potency over the initial hit 9. The fragment from this library that exhibited the highest affinity and ligand efficiency (11: K(d) = 13 μM, LE = 0.33) may serve as a starting point for development of inhibitors targeting the sY12 site.

Crystallographic Structure of Truncated CCL21 and the Putative Sulfotyrosine-Binding Site.

Molecular Modeling and Site-Directed Mutagenesis of Ccr5 Reveal Residues Critical for Chemokine Binding and Signal Transduction

Cryo-EM Structure and Biochemical Analysis of the Human Chemokine Receptor CCR8

Cryo-EM structure and biochemical analysis of human chemokine receptor CCR8

Unveiling the structural mechanisms of nonpeptide ligand recognition and activation in human chemokine receptor CCR8

Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine

Structural basis of antibody inhibition and chemokine activation of the human CC chemokine receptor 8

Structural insights into CXCR4 modulation and oligomerization

Identification and mechanism of G protein-biased ligands for chemokine receptor CCR1

Biophysical characterization of the CXC chemokine receptor 2 ligands

Structural Basis of the Interactions Between Cxcr4 and Cxcl12/Sdf-1 Revealed by Theoretical Approaches

Fragment-based Optimization of Small Molecule CXCL12 Inhibitors for Antagonizing the CXCL12/CXCR4 Interaction.

Specific binding-induced modulation of the XCL1 metamorphic equilibrium

Structural insights into the activation of chemokine receptor CXCR2

Noncanonical roles of chemokine regions in CCR9 activation revealed by structural modeling and mutational mapping

Non-full-length Water-Soluble CXCR4<SUP>QTY</SUP> and CCR5<SUP>QTY</SUP> Chemokine Receptors: Implication for Overlooked Truncated but Functional Membrane Receptors

The C-terminal peptide of CCL21 drastically augments CCL21 activity through the dendritic cell lymph node homing receptor CCR7 by interaction with the receptor N-terminus

Transcriptional Regulation of CCL20 Expression.

Exploring an Intracellular Allosteric Site of CC-Chemokine Receptor 4 from 3D Models, Probe Simulations, and Mutagenesis

Molecular Insights into Ligand Recognition and Activation of Chemokine Receptors CCR2 and CCR3